Ardelyx (ARDX) to Release Earnings on Thursday

Key Points

• Ardelyx is set to release its Q3 2025 earnings on October 30, 2025, with analysts predicting a loss of ($0.07) per share and revenue of $100.438 million for the quarter.
• In its last earnings report on August 4th, Ardelyx exceeded expectations, reporting a net revenue increase of 23.0% year-over-year and an EPS of ($0.08), compared to the consensus estimate of ($0.13).
• Institutional investors have increased their holdings in Ardelyx, with Bank of America Corp DE raising its stake by 88.8% in the second quarter, indicating strong institutional support.

Ardelyx (NASDAQ:ARDX - Get Free Report) is expected to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $100.4380 million for the quarter. Parties may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. The business had revenue of $97.66 million for the quarter, compared to analyst estimates of $82.69 million. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The company's revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.07) EPS. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Stock Performance

NASDAQ ARDX opened at $5.15 on Thursday. Ardelyx has a twelve month low of $3.21 and a twelve month high of $6.78. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -22.39 and a beta of 0.67. The company has a current ratio of 4.30, a quick ratio of 4.03 and a debt-to-equity ratio of 1.44. The stock has a 50-day moving average of $5.87 and a 200 day moving average of $4.82.

Insider Activity

In other Ardelyx news, insider Eric Duane Foster sold 15,308 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $5.93, for a total value of $90,776.44. Following the transaction, the insider directly owned 301,498 shares in the company, valued at $1,787,883.14. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael Raab sold 45,687 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $5.93, for a total transaction of $270,923.91. Following the completion of the sale, the chief executive officer directly owned 1,502,250 shares of the company's stock, valued at approximately $8,908,342.50. This trade represents a 2.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 165,551 shares of company stock valued at $996,917 over the last 90 days. Insiders own 4.80% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Ardelyx by 88.8% during the second quarter. Bank of America Corp DE now owns 5,527,988 shares of the biopharmaceutical company's stock worth $21,670,000 after purchasing an additional 2,600,080 shares during the period. Goldman Sachs Group Inc. raised its holdings in Ardelyx by 10.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company's stock valued at $11,680,000 after acquiring an additional 221,486 shares during the last quarter. AQR Capital Management LLC increased its stake in Ardelyx by 47.0% in the second quarter. AQR Capital Management LLC now owns 2,312,363 shares of the biopharmaceutical company's stock valued at $9,064,000 after purchasing an additional 739,300 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in shares of Ardelyx by 88.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 1,069,856 shares of the biopharmaceutical company's stock worth $4,194,000 after acquiring an additional 503,420 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Ardelyx by 2.9% in the 2nd quarter. Rhumbline Advisers now owns 349,133 shares of the biopharmaceutical company's stock valued at $1,369,000 after purchasing an additional 9,697 shares during the last quarter. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. UBS Group set a $12.00 price target on shares of Ardelyx in a research note on Tuesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Ardelyx in a research report on Wednesday, October 8th. Wall Street Zen upgraded Ardelyx from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Raymond James Financial began coverage on Ardelyx in a research note on Wednesday, September 3rd. They issued a "strong-buy" rating and a $14.00 price objective for the company. Finally, Piper Sandler lifted their target price on shares of Ardelyx from $8.00 to $9.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.70.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.